Literature DB >> 29018715

Reducing intraocular-pressure spike after intravitreal-bevacizumab injection with ocular decompression using a sterile cotton swab soaked in proparacaine 0.5%: A quasi-experimental study.

Naveed A Qureshi1, Hassan Mansoor1, Sabihuddin Ahmad2, Sarah Zafar1, Muhammad Asif1.   

Abstract

BACKGROUND/
PURPOSE: The study was conducted to determine the effect of preinjection ocular decompression by a cotton swab soaked in local anesthetic on the immediate postinjection rise in intraocular pressure (IOP) after intravitreal bevacizumab (IVB).
METHODS: A nonrandomized, quasi-experimental interventional study was conducted at Al-Shifa Trust Eye Hospital, Pakistan, from August 1, 2013 to July 31, 2014. One hundred (n = 100) patients receiving 0.05-mL IVB injection for the first time were assigned to two preinjection anesthetic methods: one with ocular decompression using a sterile cotton swab soaked in proparacaine 0.5%, and the other without ocular decompression using proparacaine 0.5% eyedrops. The IOP was recorded in the eye receiving IVB at three time intervals: Time 1 (preinjection), Time 2 (immediately after injection), and Time 3 (30 minutes after injection).
RESULTS: There was a significant difference in the mean IOP change (between Time 1 and Time 2) for the group injected with ocular decompression [M = 1.00, standard deviation (SD) = 1.47] and the group injected without ocular decompression (M = 5.00, SD = 2.38; t (68) = 9.761, p < 0.001). There was also a significant difference in the mean IOP change (between Time 1 and Time 3) for the group injected with ocular decompression (M = 0.428, SD = 1.58) and the group injected without ocular decompression (M = 4.318, SD = 3.34; t (58) = 7.111, p < 0.001).
CONCLUSION: Patients receiving IVB injections with ocular-decompression soaking in proparacaine 0.5% experience significantly lower postinjection IOP spike, and that too for a considerably shorter duration as compared to those receiving IVB without ocular decompression.

Entities:  

Keywords:  bevacizumab; decompression; intraocular pressure

Year:  2016        PMID: 29018715      PMCID: PMC5602693          DOI: 10.1016/j.tjo.2015.12.003

Source DB:  PubMed          Journal:  Taiwan J Ophthalmol        ISSN: 2211-5056


  17 in total

Review 1.  Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy.

Authors:  Ahmad A Aref
Journal:  Curr Opin Ophthalmol       Date:  2012-03       Impact factor: 3.761

2.  Autoregulation of human optic nerve head blood flow in response to acute changes in ocular perfusion pressure.

Authors:  C E Riva; M Hero; P Titze; B Petrig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-10       Impact factor: 3.117

3.  [Out-flow pressure, minute volume and resistance of the anterior chamber flow in man].

Authors:  H GOLDMANN
Journal:  Doc Ophthalmol       Date:  1951       Impact factor: 2.379

4.  Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.

Authors:  Judy E Kim; Anand V Mantravadi; Elizabeth Y Hur; Douglas J Covert
Journal:  Am J Ophthalmol       Date:  2008-09-05       Impact factor: 5.258

5.  Lidocaine gel anesthesia for intravitreal drug administration.

Authors:  Igor Kozak; Lingyun Cheng; William R Freeman
Journal:  Retina       Date:  2005-12       Impact factor: 4.256

6.  Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).

Authors:  Michael W Stewart; Philip J Rosenfeld; Fernando M Penha; Fenghua Wang; Zohar Yehoshua; Elena Bueno-Lopez; Pedro F Lopez
Journal:  Retina       Date:  2012-03       Impact factor: 4.256

7.  Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.

Authors:  Quan V Hoang; Luis S Mendonca; Kara E Della Torre; Jesse J Jung; Angela J Tsuang; K Bailey Freund
Journal:  Ophthalmology       Date:  2011-11-04       Impact factor: 12.079

8.  Randomized trial of anesthetic methods for intravitreal injections.

Authors:  Gregory R Blaha; Elisha P Tilton; Fina C Barouch; Jeffrey L Marx
Journal:  Retina       Date:  2011-03       Impact factor: 4.256

9.  Short-term intraocular pressure changes after intravitreal injection of bevacizumab.

Authors:  Hussein Hollands; Jonathan Wong; Robin Bruen; Robert J Campbell; Sanjay Sharma; Jeffery Gale
Journal:  Can J Ophthalmol       Date:  2007-12       Impact factor: 1.882

10.  Ocular decompression with cotton swabs lowers intraocular pressure elevation after intravitreal injection.

Authors:  Ninel Z Gregori; Matthew J Weiss; Raquel Goldhardt; Joyce C Schiffman; Edgardo Vega; Cherrie-Ann Mattis; Wei Shi; Linda Kelley; Vilma Hernandez; William J Feuer
Journal:  J Glaucoma       Date:  2014 Oct-Nov       Impact factor: 2.503

View more
  3 in total

1.  Reduction of Intraocular Pressure Spikes Due to Intravitreal Bevacizumab Injections by Scleral Indentation with Cotton Swab or Digital Ocular Massage: Innovative Techniques Compared.

Authors:  Raffaele Nuzzi; Simona Scalabrin; Alice Becco
Journal:  Clin Ophthalmol       Date:  2020-08-27

2.  Transient Vision Loss Associated with Prefilled Aflibercept Syringes: A Case Series and Analysis of Injection Force.

Authors:  Daniel J Lee; Brittni A Scruggs; Erik Sánchez; Merina Thomas; Ambar Faridi
Journal:  Ophthalmol Sci       Date:  2022-01-21

3.  High Density Display of an Anti-Angiogenic Peptide on Micelle Surfaces Enhances Their Inhibition of αvβ3 Integrin-Mediated Neovascularization In Vitro.

Authors:  Rajini Nagaraj; Trevor Stack; Sijia Yi; Benjamin Mathew; Kenneth R Shull; Evan A Scott; Mathew T Mathew; Divya Rani Bijukumar
Journal:  Nanomaterials (Basel)       Date:  2020-03-22       Impact factor: 5.076

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.